Latest papers

8 papers1 paper in the last four weeks, against 1 the four weeks before. 0.0% of all new papers.

Nov 15, 2026

Reasoning in the loop: antibody lead optimization by probing mechanism and measurement

Lab-in-the-loop systems, in which a model proposes molecules, automated assays measure their properties and the results retrain the model, are a popular approach to antibody lead optimization. These systems optimize for a specification defined with metrics computed from instrument signals, so their success depends on how well those metrics serve as proxies for the properties a drug candidate needs. When a metric is a poor proxy, neither a better model nor more data will fix it, and identifying the problem usually requires expert review. We report two campaigns run on BigHat Biosciences' Milliner platform, one on an anti-albumin nanobody (VHH) and one on an anti-mesothelin single-chain variable fragment (scFv), in which a research team and a general-purpose AI agent, Claude, brought scientific reasoning into the loop. Over seven rounds and about 1,010 design variants we built libraries from antibody lineage, structure and biophysics, and found from the raw curves that on each scaffold one thermal metric did not measure what its name implied. The libraries were built as controlled comparisons, so the results also show what each mutation contributes to each property. We fit a physical model of the curves, used it to choose metrics suited to each scaffold, and changed the experimental protocol, varying protein concentration and heating rate, to test the model against pre-registered predictions. Both leads improve on their parents in affinity, thermal stability and aggregation while improving or maintaining yield and purity.
Sep 28, 2026

AbGaze: Attentive Geometric Representation Learning for End-to-End Antibody Design

Computational antibody design requires representations that capture the geometric patterns underlying antigen--antibody interactions, yet existing approaches often rely on scalar distances or surface-intrinsic features, leaving cross-molecular geometry largely implicit. We present AbGaze, an end-to-end antibody design framework based on attentive geometric representation learning, which encodes distance, spatial direction, and surface-normal orientation of antigen surfaces relative to antibody-residue local frames, and adaptively aggregates these geometric interactions according to their interfacial context. The learned interaction representation is shared across multi-CDR co-design, complex structure prediction, and affinity optimization, with local-frame geometric supervision further constraining the representation. AbGaze outperforms prior methods across all three tasks: relative to the second-best method, it improves amino-acid recovery by 7.1% and reduces structural error by 14.9% on average over the six CDRs, improves interface docking quality (DockQ) by 6.6%, and raises the affinity improvement rate (IMP) by 32.5%.
May 7, 2026

Conditional generation of antibody sequences with classifier-guided germline-absorbing discrete diffusion

Antibody therapeutics are among the most successful modern medicines, yet computationally designing antibodies with desirable binding and developability properties remains challenging. While protein language models (pLMs) have emerged as powerful tools for antibody sequence design, existing approaches largely suffer from two key limitations: they predominantly memorize germline sequences rather than modeling biologically meaningful somatic variation, and they offer limited support for flexible classifier-guided conditional generation. We address these challenges through two primary contributions. First, we demonstrate that discrete diffusion fine-tuning achieves strong language modeling performance on antibody sequences while allowing for generation conditioned on any off-the-shelf classifier. Second, we introduce germline absorbing diffusion, a novel modification of the discrete diffusion noise process in which the germline sequence - rather than a masked sequence - serves as the absorbing state. This biologically motivated inductive bias restricts the model to learning the trajectory from germline to observed sequence, effectively excluding genetic variation and V(D)J recombination statistics from the learned distribution and dramatically mitigating germline bias. We show that germline diffusion improves non-germline residue prediction accuracy from 26 percent to 46 percent, approaching the theoretical upper bound set by true biological variability. We then demonstrate the utility of our germline diffusion model on the conditional generation tasks of sampling antibodies with improved hydrophobicity and predicted binding affinity. On both tasks our model shows an improved tradeoff between class adherence and sample quality, significantly outperforming EvoProtGrad, a popular strategy to sample from pLMs with gradient-based discrete Markov Chain Monte Carlo.
Apr 15, 2026

BOAT: Navigating the Sea of In Silico Predictors for Antibody Design via Multi-Objective Bayesian Optimization

Antibody lead optimization is inherently a multi-objective challenge in drug discovery. Achieving a balance between different drug-like properties is crucial for the development of viable candidates, and this search becomes exponentially challenging as desired properties grow. The ever-growing zoo of sophisticated in silico tools for predicting antibody properties calls for an efficient joint optimization procedure to overcome resource-intensive sequential filtering pipelines. We present BOAT, a versatile Bayesian optimization framework for multi-property antibody engineering. Our `plug-and-play' framework couples uncertainty-aware surrogate modeling with a genetic algorithm to jointly optimize various predicted antibody traits while enabling efficient exploration of sequence space. Through systematic benchmarking against genetic algorithms and newer generative learning approaches, we demonstrate competitive performance with state-of-the-art methods for multi-objective protein optimization. We identify clear regimes where surrogate-driven optimization outperforms expensive generative approaches and establish practical limits imposed by sequence dimensionality and oracle costs.
Mar 13, 2026

CHIMERA-Bench: A Benchmark Dataset for Epitope-Specific Antibody Design

Computational antibody design has seen rapid methodological progress, with dozens of deep generative methods proposed in the past three years, yet the field lacks a standardized benchmark for fair comparison and model development. These methods are evaluated on different SAbDab snapshots, non-overlapping test sets, and incompatible metrics, and the literature fragments the design problem into numerous sub-tasks with no common definition. We introduce CHIMERA-Bench: (CDR Modeling with Epitope-guided Redesign), a unified benchmark built around a single canonical task: epitope-conditioned CDR sequence-structure co-design. CHIMERA-Bench provides three components. The first is a curated, deduplicated dataset of 2,922 antibody-antigen complexes with epitope and paratope annotations. The second is a set of three biologically motivated splits that test generalization to unseen epitopes, unseen antigen folds, and prospective temporal targets. The third is a comprehensive evaluation protocol with five metric groups, including novel epitope-specificity measures. We benchmark eleven methods spanning six generative paradigms and report results across all splits. CHIMERA-Bench is the largest dataset of its kind for the antibody design problem, allowing the community to develop and test novel methods and evaluate their generalizability.
Mar 11, 2026

How to make the most of your masked language model for protein engineering

A plethora of protein language models have been released in recent years. Yet comparatively little work has addressed how to best sample from them to optimize desired biological properties. We fill this gap by proposing a flexible, effective sampling method for masked language models (MLMs), and by systematically evaluating models and methods both in silico and in vitro on actual antibody therapeutics campaigns. Firstly, we propose sampling with stochastic beam search, exploiting the fact that MLMs are remarkably efficient at evaluating the pseudo-perplexity of the entire 1-edit neighborhood of a sequence. Reframing generation in terms of entire-sequence evaluation enables flexible guidance with multiple optimization objectives. Secondly, we report results from our extensive in vitro head-to-head evaluation for the antibody engineering setting. This reveals that the choice of sampling method can have a substantial impact, motivating future research into this under-explored area.
Feb 21, 2026

Conditionally Site-Independent Neural Evolution of Antibody Sequences

Common deep learning approaches for antibody engineering focus on modeling the marginal distribution of sequences. By treating sequences as independent samples, however, these methods overlook affinity maturation as a rich and largely untapped source of information about the evolutionary process by which antibodies explore the underlying fitness landscape. In contrast, classical phylogenetic models explicitly represent evolutionary dynamics but lack the expressivity to capture complex epistatic interactions. We bridge this gap with CoSiNE, a continuous-time Markov chain parameterized by a deep neural network. Mathematically, we prove that CoSiNE provides a first-order approximation to the intractable sequential point mutation process, capturing epistatic effects with an error bound that is quadratic in branch length. Empirically, CoSiNE outperforms state-of-the-art language models in zero-shot variant effect prediction by explicitly disentangling selection from context-dependent somatic hypermutation. Finally, we introduce Guided Gillespie, a classifier-guided sampling scheme that steers CoSiNE at inference time, enabling efficient optimization of antibody binding affinity toward specific antigens.
May 23, 2025

A Comprehensive Benchmark of Computational Models for Antibody--Antigen Binding Affinity

Computational antibody design requires benchmarks that measure functional binding rather than similarity to natural sequences. Here we present AbBiBench, which treats the antibody--antigen complex as the evaluation unit and harmonizes 216,560 experimental measurements spanning 13 antibodies and 9 antigens. We compare 20 computational approaches without task-specific training or fine-tuning. The analyses show that global structure-conditioned inverse folding yields the strongest and most consistent affinity rankings, whereas antibody-specific fine-tuning does not consistently improve performance. Across models, rankings are more useful for prioritizing likely affinity gains than for excluding weak variants. In a subsequent case study, multi-objective evaluation of model-generated F045-092 CDR-H3 variants for H1N1 binding revealed a trade-off between predicted binding potential and evolutionary sequence plausibility; all 21 selected candidates produced H1-reactive ELISA signals. AbBiBench provides an open framework for developing and evaluating function-aware antibody design methods.
May 18, 2025

AbFlowNet: Optimizing Antibody-Antigen Binding Energy via Diffusion-GFlowNet Fusion

Complementarity Determining Regions (CDRs) are critical segments of an antibody that facilitate binding to specific antigens. Current computational methods for CDR design utilize reconstruction losses and do not jointly optimize binding energy, a crucial metric for antibody efficacy. Rather, binding energy optimization is done through computationally expensive Online Reinforcement Learning (RL) pipelines rely heavily on unreliable binding energy estimators. In this paper, we propose AbFlowNet, a novel generative framework that integrates GFlowNet with Diffusion models. By framing each diffusion step as a state in the GFlowNet framework, AbFlowNet jointly optimizes standard diffusion losses and binding energy by directly incorporating energy signals into the training process, thereby unifying diffusion and reward optimization in a single procedure. Experimental results show that AbFlowNet outperforms the base diffusion model by 3.06% in amino acid recovery, 20.40% in geometric reconstruction (RMSD), and 3.60% in binding energy improvement ratio. ABFlowNet also decreases Top-1 total energy and binding energy errors by 24.8% and 38.1% without pseudo-labeling the test dataset or using computationally expensive online RL regimes.